BioMarin Pharma (BMRN) Misses Q1 EPS by 7c; Raises FY12 Sales Guidance
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $55.44 +1.37%
EPS Growth %: -34.0%
Financial Fact:
Total operating expenses: 339.98M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -34.0%
Financial Fact:
Total operating expenses: 339.98M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q1 EPS of ($0.21), $0.07 worse than the analyst estimate of ($0.14). Revenue for the quarter came in at $116.6 million versus the consensus estimate of $119.24 million.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Sees FY2012 revenue of $475-$510 million, versus prior guidance of $465-$510 million and the consensus of $487.87 million.
For earnings history and earnings-related data on BioMarin Pharmaceuticals, Inc. (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Middleby board approves spin-off of food processing unit Midera
- Goldman reinstates Estee Lauder rating, sees turnaround driving growth and margins
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
